JP Morgan maintains Corpay at Overweight, raises price target to $500 from $470

JP Morgan maintained its Overweight rating on Corpay and raised its price target to $500 from $470, suggesting an 11.9% upside from the Nov 5 close of $447. Recent analyst price targets for Corpay range from $460 to $539.

Original reporting
Published Nov 5, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Corpay at Overweight, raises price target to $500 from $470 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The analyst upgrade may attract short‑term buying interest, but lacks a concrete catalyst beyond the rating change.

02

Market read

Analyst rating change offers a modest trade idea for Corpay investors.

03

What to watch

No new fundamental data; price target reflects analyst optimism rather than operational change.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

JP Morgan upgraded Corpay to Overweight and increased its price target from $470 to $500.

Market effects

Analyst target raise may modestly lift fintech sector sentiment.

Limited to US equity markets where Corpay is tracked.

Minimal global impact.

Counterpoint

Target raise could be premature if broader market volatility persists.

Key entities

  • JP Morgan

    Investment bank providing the rating and target.

  • Corpay

    Fintech firm subject of the rating.

Related articles

$CPAYMed

What Corpay (CPAY) Said on Its Q3 Earnings Call

Corpay (CPAY) reported Q3 gross margin at 30.4%, up from Q2 but down annually. Cash position was CAD 50.6M. Acquired AISPECO for airborne sensors. Expects revenue synergies sooner. Plans to scale manufacturing and expand commercial/defense businesses. Corpay provides corporate payment solutions.

$CPAYMedAI 8/10

Corpay 3Q 2026: Revenue $1.38B, EPS $5.66 — 10-Q Summary

Corpay reported 3Q 2026 revenue of $1.38B, up 17.9% YoY, and net income of $378.42M, up 36.2% YoY. Growth was driven by organic spend and transaction volumes, new sales, and acquisitions. Higher operating expenses and other costs partly offset gains. Management expects liquidity to meet needs for the next 12 months.

$CPAYHighAI 8/10

Corpay (CPAY) Q3 2026 Earnings Call Transcript

Corpay (CPAY) raised Q4 2026 revenue guidance to $1.37B and cash EPS to $7.65, up 27%. Full-year 2026 revenue is expected to rise 18%, with cash EPS up over 30%. For 2027, Corpay anticipates 9-11% organic revenue growth. The company has divested noncore businesses, using proceeds for share buybacks, and plans to allocate $2B in free cash flow to acquisitions or buybacks. Corporate Payments segment growth is expected to remain in the high teens.

$CPAYMed

Corpay Q3 Earnings Call Highlights

Corpay (NYSE:CPAY) expects 9-11% organic revenue growth in 2027, with $2B in free cash flow for acquisitions or share repurchases. The company divested noncore businesses in 2026, using proceeds for buybacks. Alpha and Avid are expected to contribute over $1.40 in combined cash EPS accretion in 2026. Corpay aims to compound adjusted EPS by over 20% annually through 2029.

$CPAYMed

Corpay Inc (CPAY) (Q3 2026) Earnings Call Highlights: Sixth Straight Quarter

Corpay Inc (CPAY) reported Q3 2026 earnings, guiding Q4 organic revenue growth at 10%, slightly below Q3's 11%. Corporate payments growth is ~17% excluding one-time items, while lodging and vehicle payments show mixed results. The company may pursue divestitures and is uncertain about acquiring the remaining stake in Avid. Operating costs rose 9%, and tax rate decreased to 23.4%. CEO Ronald Clarke highlighted strong corporate payments growth and potential for 2027.